УКР  |  ENG

Клинические исследования в Украине

Форум Пациентам

Исследования / № 00716859

Описание
Краткое названиеA Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
Полное названиеA Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study Evaluating The Efficacy And Safety Of Latanoprost And Timolol In Pediatric Subjects With Glaucoma.
СпонсорPfizer
Industry
ИсточникPfizer
Под контролемUnited States: Food and Drug Administration
Yes
Краткое описаниеTo assess the effectiveness of latanoprost 0.005% ophthalmic solution dosed once-daily and
timolol 0.5% dosed twice-daily in paediatric subjects of 18 years of age or under who are
diagnosed with glaucoma.
СостояниеЗавершено
Дата началаJuly 2008
ФазаPhase 3
Вид исследованияAllocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Набор0
КритерииInclusion Criteria:

- Male or female of 18 years of age or under

- Diagnosis of glaucoma

- IOP of 22 mmHg or above in at least 1 eye

Exclusion Criteria:

- Require surgery for acute angle closure

- Have had prior cyclodestructive procedures

- Have a history of ocular trauma or surgery in either eye within 3 months of the
baseline visit
ПолBoth
Минимальный возраст36 Weeks
Максимальный возраст18 Years
УсловиеGlaucoma
Применяемое лечение
DrugTimolol
Druglatanoprost
Контакты и расположение
Kharkiv , 61000Pfizer Investigational Site
Kyiv Pfizer Investigational Site
Kyiv , 01135Pfizer Investigational Site
Kyiv , 04050Pfizer Investigational Site
Odesa , 65061Pfizer Investigational Site
2011 © Клинические испытания в Украине